Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
RemeGen Co., Ltd.
With
This is a Phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy and safety of Telitacicept in subjects with Ocular Myasthenia Gravis (OMG). The study will be conducted at multiple centers. Eligible subjects will be randomized in a 1:1 ratio to one of two treatment arms: Arm 1: Telitacicept Arm 2: Placebo Randomization will be stratified by two factors: Acetylcholine Receptor (AChR) antibody status (positive vs. negative) and age (\<18 years vs. ≥18 years). Primary Objective: To evaluate the efficacy of Telitacicept compared to placebo in the treatment of subjects with Ocular Myasthenia Gravis. Primary Endpoint: Change from baseline in the Myasthenia Gravis Impairment Index (Patient-Reported Outcomes) \[MGII (PRO)\] ocular score at Week 24. Study Population: A total of approximately 120 subjects will be enrolled. Intervention: Subjects will receive either Telitacicept or a matching placebo. The dose will be determined based on the subject's age and body weight at baseline. The placebo will be identical in appearance to Telitacicept to maintain the blind. Safety Assessments: Safety and tolerability will be assessed through the monitoring and recording of adverse events (AEs), serious adverse events (SAEs), vital signs, physical examinations, and regular laboratory tests (hematology, serum chemistry, urinalysis). An independent Data Monitoring Committee (DMC) will be established to monitor the safety of the trial.
Age
12–80
Sex
ALL
Healthy volunteers
Not accepted
